--- title: "Contract Research 13Fs: IQVIA, Icon, Medpace, Charles River" type: learn slug: cro-13f-iqv-iclr-medp-decoder canonical_url: https://13finsight.com/learn/cro-13f-iqv-iclr-medp-decoder published_at: 2026-05-16T08:43:34.267Z updated_at: 2026-05-16T08:43:37.977Z author: Sarah Mitchell author_title: Education Editor author_url: https://13finsight.com/authors/sarah-mitchell word_count: 403 locale: en source: 13F Insight --- # Contract Research 13Fs: IQVIA, Icon, Medpace, Charles River > IQVIA Holdings, ICON plc, Medpace Holdings, Charles River Laboratories, and Syneos Health anchor US-traded contract research organization (CRO) 13F positioning. Pharma R&D outsourcing cycles, AI integration, biotech funding dynamics, and emerging trial complexity drive distinctive institutional patterns. US-traded contract research organization (CRO) equities form a distinctive healthcare-services corner of institutional 13F positioning. IQVIA Holdings (IQV), ICON plc (ICLR), Medpace Holdings (MEDP), Charles River Laboratories International (CRL), and Syneos Health (private, post-2023 take-private) anchor the cohort. Multi-year pharma R&D outsourcing cycles, emerging AI integration, biotech funding dynamics, and emerging trial complexity drive distinctive institutional patterns. Reading CRO 13F positioning requires understanding the pharma-outsourcing framework plus the multi-year biotech-and-AI cycle dynamics.The CRO business modelCROs face four primary economic drivers:Pharma R&D outsourcing cycles. Multi-decade pharma R&D outsourcing growth driven by complexity, cost containment, plus emerging biotech ecosystem. Multi-year R&D spending drives baseline demand.Biotech funding dynamics. Multi-year biotech funding cycles (venture, IPO, follow-on) drive emerging biotech CRO demand. Multi-year biotech funding compression (2022-2024) reduced CRO biotech segment.AI integration. Multi-year emerging AI integration into clinical trials (site selection, patient recruitment, data analytics, regulatory submissions) drives operator productivity plus emerging product differentiation.Trial complexity. Multi-year emerging trial complexity (cell-and-gene therapy, oncology combination trials, rare disease) drives premium pricing plus emerging specialty CRO opportunities.Major US-traded CRO namesIQVIA Holdings (IQV)Largest global CRO with diversified Technology & Analytics Solutions plus R&D Solutions plus Contract Sales & Medical Solutions. Multi-decade IMS Health heritage plus emerging emerging biomarker plus data services.ICON plc (ICLR)Diversified CRO across full-service trials plus emerging clinical research support. Multi-year post-PRA Health Sciences merger operational integration.Medpace Holdings (MEDP)Specialty therapeutic-area focused CRO (oncology, rare disease, metabolic, cardiology, neurology). Multi-decade Cincinnati-based franchise plus operational discipline.Charles River Laboratories (CRL)Diversified across Research Models and Services (RMS), Discovery and Safety Assessment (DSA), Manufacturing Solutions. Multi-decade research model franchise.Syneos Health (private post-2023)Diversified CRO plus emerging Commercial Solutions. Taken private 2023 by Elliott Management plus Patient Square Capital plus Veritas Capital.How institutional managers position around CROsThree patterns:Pattern 1: Diversified-platform concentrationIQV-concentrated active manager positions reflect diversified CRO platform plus technology services thesis.Pattern 2: Specialty-CRO positioningMEDP-concentrated active manager positions reflect specialty therapeutic-area focus thesis.Pattern 3: Research-models positioningCRL-concentrated active manager positions reflect research models plus diversified franchise thesis.How to read CRO 13F positioningThree rules:Rule 1: Identify segment exposureFull-service trials vs research models vs specialty focus have distinct economics.Rule 2: Watch backlog disclosureMulti-year backlog plus book-to-bill ratios drive multi-quarter visibility.Rule 3: Cross-check biotech fundingMulti-year biotech funding cycles drive CRO biotech segment.What CRO positioning signalsDiversified-platform conviction. Concentrated IQV positions signal diversified platform thesis.Specialty-CRO conviction. Concentrated MEDP positions signal specialty focus thesis.Research-models conviction. Concentrated CRL positions signal research models franchise thesis.For real-time tracking of CRO 13F activity, see the institutional signals feed. ## FAQ ### What are the major US-traded CRO companies? Five major US-traded CROs: (1) IQVIA Holdings (IQV) — largest global with Technology & Analytics, R&D Solutions, Contract Sales & Medical; (2) ICON plc (ICLR) — diversified post-PRA Health Sciences merger; (3) Medpace Holdings (MEDP) — specialty therapeutic-area focused; (4) Charles River Laboratories (CRL) — Research Models, Discovery and Safety Assessment, Manufacturing Solutions; (5) Syneos Health (private post-2023 take-private). ### How does pharma R&D outsourcing work? Multi-decade pharma R&D outsourcing growth driven by clinical trial complexity, cost containment imperatives, plus emerging biotech ecosystem requiring outsourced services. Multi-year pharma R&D spending (estimated $250+ billion annually) plus expanding outsourced share (50%+ for major pharma) drives baseline demand. Multi-year emerging large molecule plus cell-and-gene therapy trials drive premium pricing. Reading pharma R&D disclosure drives positioning. ### How do biotech funding cycles affect CROs? Multi-year biotech funding cycles (venture capital, IPO, follow-on offerings) drive emerging biotech CRO demand. Multi-year biotech funding compression (2022-2024 substantial reduction from 2020-2021 peak) reduced CRO biotech segment substantially. Multi-year biotech funding recovery plus emerging biotech IPO activity drive CRO biotech segment recovery. Reading biotech funding data drives institutional positioning. ### How does AI integration affect CROs? Multi-year emerging AI integration into clinical trials (site selection, patient recruitment, data analytics, regulatory submissions) drives operator productivity plus emerging product differentiation. IQVIA particularly leverages emerging AI capabilities through Technology & Analytics segment. Multi-year emerging AI clinical scribes plus emerging AI clinical decision support plus emerging AI prior authorization expand CRO addressable services. Reading AI integration drives positioning. ### What is Medpace's specialty CRO model? Medpace Holdings operates therapeutic-area-focused specialty CRO with emphasis on oncology, rare disease, metabolic, cardiology, neurology trials. Multi-decade Cincinnati-based franchise plus operational discipline plus founder-led management (August Troendle CEO) drives consistent execution. Multi-year emerging emerging cell-and-gene therapy plus emerging precision medicine drives specialty premium. Concentrated active manager MEDP positions reflect specialty thesis. ### What signals CRO cycle inflections? Four signals: (1) pharma R&D spending plus outsourcing share trajectory; (2) biotech funding cycle data; (3) emerging AI integration plus productivity gains; (4) emerging cell-and-gene therapy plus rare disease trial demand. Concentrated 13F changes around these signals reveal manager cycle reading. --- Source: 13F Insight — https://13finsight.com/learn/cro-13f-iqv-iclr-medp-decoder Author: Sarah Mitchell — https://13finsight.com/authors/sarah-mitchell Last updated: 2026-05-16T08:43:37.977Z